Longboard Financial Statements From 2010 to 2024

LBPH Stock  USD 59.77  0.07  0.12%   
Longboard Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Longboard Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Longboard Pharmaceuticals financial statements helps investors assess Longboard Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Longboard Pharmaceuticals' valuation are summarized below:
Market Capitalization
2.3 B
Earnings Share
(2.25)
We have found ninety-two available fundamental ratios for Longboard Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Longboard Pharmaceuticals last-minute fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year. The Longboard Pharmaceuticals' current Market Cap is estimated to increase to about 156.9 M, while Enterprise Value is projected to decrease to under 117 M.
Check Longboard Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Longboard Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 2.3 M, Interest Income of 2.3 M or Depreciation And Amortization of 3.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.92. Longboard financial statements analysis is a perfect complement when working with Longboard Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Longboard Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.

Longboard Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets57.3 M50.7 M60.4 M
Slightly volatile
Other Current Liabilities5.8 M8.3 M3.1 M
Slightly volatile
Total Current Liabilities7.5 M9.8 M4.4 M
Slightly volatile
Total Stockholder Equity51.8 M40.9 M56.1 M
Pretty Stable
Accounts Payable910.4 KM1.2 M
Slightly volatile
Cash13.6 M14.3 M47.6 M
Slightly volatile
Non Current Assets Total539.6 K476 K799.8 K
Slightly volatile
Non Currrent Assets Other28.2 K29.7 K650.7 K
Slightly volatile
Cash And Short Term Investments55.6 M48.5 M59.1 M
Pretty Stable
Common Stock Shares Outstanding20.5 M22.7 M18.1 M
Slightly volatile
Liabilities And Stockholders Equity57.3 M50.7 M60.4 M
Slightly volatile
Other Current AssetsM1.7 M654.2 K
Slightly volatile
Other Stockholder Equity134 M181.6 M49.2 M
Slightly volatile
Total Liabilities7.6 M9.8 M4.4 M
Slightly volatile
Deferred Long Term Liabilities700.8 K788.4 K858.5 K
Slightly volatile
Total Current Assets56.8 M50.2 M59.6 M
Slightly volatile
Capital Stock1.9 KK40.9 M
Slightly volatile
Net Working Capital51.3 M40.4 M55.4 M
Pretty Stable
Short and Long Term Debt Total463.7 K475 K531.1 K
Very volatile
Non Current Liabilities Other148 K166.5 K181.3 K
Slightly volatile
Short Term Debt429.7 K475 K355.4 K
Slightly volatile
Common Stock1.5 KK1.1 K
Slightly volatile
Property Plant Equipment7.7 K8.1 K429.7 K
Slightly volatile
Common Stock Total Equity800900980
Slightly volatile
Capital Surpluse118.6 M133.5 M145.3 M
Slightly volatile
Long Term Investments26.4 K29.7 K32.3 K
Slightly volatile

Longboard Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.6 K4.5 K6.1 K
Slightly volatile
Selling General Administrative11.3 M13 M10 M
Slightly volatile
Other Operating Expenses39.5 M56.8 M21.8 M
Slightly volatile
Research Development28.3 M43.8 M11.8 M
Slightly volatile
Total Operating Expenses39.5 M56.8 M21.8 M
Slightly volatile
Cost Of RevenueK5.8 K1.8 K
Slightly volatile
Selling And Marketing ExpensesK4.5 K4.9 K
Slightly volatile

Longboard Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.3 M3.3 MM
Slightly volatile
Change In Working Capital1.6 M1.3 M2.3 M
Slightly volatile
Begin Period Cash Flow10.2 M10.8 M9.8 M
Slightly volatile
Depreciation3.3 K5.8 K1.7 K
Slightly volatile
Change To Operating Activities1.9 M3.3 M1.5 M
Slightly volatile
Issuance Of Capital Stock38.5 M29 M52.8 M
Slightly volatile
End Period Cash Flow13.6 M14.3 M47.6 M
Slightly volatile
Change To Netincome3.5 M2.4 MM
Slightly volatile
Cash Flows Other Operating1.4 M1.6 M1.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio2.923.34874.5945
Slightly volatile
Book Value Per Share1.711.80073.0807
Very volatile
PB Ratio2.923.34874.5945
Slightly volatile
Payables Turnover0.00260.0050.0015
Slightly volatile
Cash Per Share4.252.1343.4012
Slightly volatile
Income Quality0.580.93470.3933
Slightly volatile
Net Debt To EBITDA0.230.24413.0212
Slightly volatile
Current Ratio4.885.138215.4766
Slightly volatile
Tangible Book Value Per Share1.711.80073.0807
Very volatile
Graham Number9.289.84998.6606
Slightly volatile
Shareholders Equity Per Share1.711.80073.0807
Very volatile
Capex Per Share8.0E-48.0E-49.0E-4
Slightly volatile
Graham Net Net1.621.70393.0096
Very volatile
Interest Debt Per Share0.0390.04390.0478
Slightly volatile
Price Book Value Ratio2.923.34874.5945
Slightly volatile
Ebt Per Ebit1.080.95881.0001
Pretty Stable
Effective Tax Rate0.01830.01750.0046
Slightly volatile
Company Equity Multiplier0.91.23881.0661
Very volatile
Quick Ratio4.885.138215.4766
Slightly volatile
Net Income Per E B T1.091.131.0115
Slightly volatile
Cash Ratio1.391.466214.0243
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9806
Slightly volatile
Price To Book Ratio2.923.34874.5945
Slightly volatile
Price Fair Value2.923.34874.5945
Slightly volatile

Longboard Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap156.9 M137 M244.6 M
Slightly volatile
Enterprise Value117 M123.2 M195.4 M
Slightly volatile

Longboard Fundamental Market Drivers

Cash And Short Term Investments48.5 M

Longboard Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Longboard Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Longboard Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Longboard Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-427.5 K-406.1 K
Cost Of Revenue5.8 KK

Currently Active Assets on Macroaxis

When determining whether Longboard Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Longboard Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Longboard Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Longboard Pharmaceuticals Stock:
Check out the analysis of Longboard Pharmaceuticals Correlation against competitors.
For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.25)
Return On Assets
(0.31)
Return On Equity
(0.47)
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.